List/Grid

Oncology Subscribe to Oncology

European consensus on methodological recommendations for clinical studies in rare cancers

European consensus on methodological recommendations for clinical studies in rare cancers

One out of every five new cancer patients is diagnosed with a rare cancer, yet the clinical evidence needed to effectively treat these rare cancer patients is scarce. Indeed, conventional cancer clinical trial methodologies require large numbers of patients who are difficult to accrue in the situation of rare cancers. Continue reading

Mushroom extract, AHCC, helpful in treating HPV

Mushroom extract, AHCC, helpful in treating HPV

A Japanese mushroom extract appears to be effective for the eradication of human papillomavirus (HPV), according to a pilot clinical trial at The University of Texas Health Science Center at Houston (UTHealth) Medical School. The results were presented at the 11th International Conference of the Society for Integrative Oncology in Houston today by principal investigator Judith A. Smith, Pharm.D., associate professor in the Department of Obstetrics, Gynecology and Reproductive Sciences at the UTHealth Medical School. Continue reading

Prognostic factors identified for peripheral squamous cell carcinomas of the lung

Prognostic factors identified for peripheral squamous cell carcinomas of the lung

A better survival outcome is associated with low blood levels of squamous cell carcinoma antigen, or absence of tumor invasion either into the space between the lungs and chest wall or into blood vessels of individuals with a peripheral squamous cell carcinoma, a type of non-small cell lung cancer (NSCLC). Lung cancer is the most common cause of cancer-related death worldwide and lung squamous cell carcinomas (SCC) account for 20-30% of all NSCLC. Continue reading

Novel software application can stratify early-stage non-small cell lung cancer patients

Novel software application can stratify early-stage non-small cell lung cancer patients

Computer-Aided Nodule Assessment and Risk Yield, is a novel software tool developed at Mayo Clinic that can automatically quantitate adenocarcinoma pulmonary nodule characteristics from non-invasive high resolution computed tomography (HRCT) images and stratify non-small cell lung cancer (NSCLC) patients into risk groups that have significantly different disease-free survival outcomes. Continue reading

Novel software application can stratify early-stage non-small cell lung cancer patients

Novel software application can stratify early-stage non-small cell lung cancer patients

Computer-Aided Nodule Assessment and Risk Yield, is a novel software tool developed at Mayo Clinic that can automatically quantitate adenocarcinoma pulmonary nodule characteristics from non-invasive high resolution computed tomography (HRCT) images and stratify non-small cell lung cancer (NSCLC) patients into risk groups that have significantly different disease-free survival outcomes. Continue reading

Anaplastic lymphoma kinase immunohistochemistry testing comparable to, if not better than, fluorescence in situ hybridization testing

Anaplastic lymphoma kinase immunohistochemistry testing comparable to, if not better than, fluorescence in situ hybridization testing

Sixteen institutions across Europe collaborated together to show for the first time that a semi-quantitative anaplastic lymphoma kinase (ALK) protein expression test, immunohistochemistry (IHC), is reliable amongst several laboratories and reviewers when test methodology and result interpretation are strictly standardized and the scoring pathologists are appropriately trained on the test. ALK tyrosine kinase inhibitors (TKIs) shrink tumors and increase progression-free survival in late-stage non-small cell lung cancer (NSCLC) patients positive for ALK as determined by the fluorescence in situ hybridization (FISH) test, a test for DNA rearrangement within the gene. Continue reading

Anaplastic lymphoma kinase immunohistochemistry testing comparable to, if not better than, fluorescence in situ hybridization testing

Anaplastic lymphoma kinase immunohistochemistry testing comparable to, if not better than, fluorescence in situ hybridization testing

Sixteen institutions across Europe collaborated together to show for the first time that a semi-quantitative anaplastic lymphoma kinase (ALK) protein expression test, immunohistochemistry (IHC), is reliable amongst several laboratories and reviewers when test methodology and result interpretation are strictly standardized and the scoring pathologists are appropriately trained on the test. ALK tyrosine kinase inhibitors (TKIs) shrink tumors and increase progression-free survival in late-stage non-small cell lung cancer (NSCLC) patients positive for ALK as determined by the fluorescence in situ hybridization (FISH) test, a test for DNA rearrangement within the gene. Continue reading

Fast modeling of cancer mutations

Fast modeling of cancer mutations

Sequencing the genomes of tumor cells has revealed thousands of genetic mutations linked with cancer. However, sifting through this deluge of information to figure out which of these mutations actually drive cancer growth has proven to be a tedious, time-consuming process. MIT researchers have now developed a new way to model the effects of these genetic mutations in mice Continue reading

Patients treated with radiation therapy who have tumors in left breast have comparable overall survival to those with tumors in right breast

Patients treated with radiation therapy who have tumors in left breast have comparable overall survival to those with tumors in right breast

Tumor laterality (left-side vs. right-side) does not impact overall survival in breast cancer patients treated with breast-conserving surgery and adjuvant external beam radiation therapy, according to a study published in the October 1, 2014 issue of the International Journal of Radiation Oncology • Biology • Physics (Red Journal), the official scientific journal of the American Society for Radiation Oncology (ASTRO). Studies have shown that breast cancer patients treated with radiation therapy have improved local-regional recurrence, and breast cancer-specific survival after breast-conserving surgery and overall survival (OS) after mastectomy Continue reading